Quantcast
Last updated on April 16, 2014 at 5:31 EDT

Latest Lymphocytic Leukemia Stories

2014-01-07 12:26:56

SUNNYVALE, Calif., Jan. 7, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that an Independent Data Monitoring Committee (IDMC) unanimously recommended that the Phase III RESONATE study, PCYC-1112-CA, a head-to-head comparison of IMBRUVICA(TM) (ibrutinib) versus ofatumumab, be stopped early because the primary and a key secondary endpoint of the study have been met. At the planned interim analysis, the Phase III RESONATE study demonstrated that IMBRUVICA showed...

2013-12-16 23:21:01

RnRMarketResearch.com adds “Acute Lymphocytic Leukemia Therapeutics Market (Pipeline Forecast & Market Forecast in G8 Countries) (2010 – 2020)” to its store. The growing acute lymphocytic leukemia population is an impetus for the growth of the market. Dallas, TX (PRWEB) December 16, 2013 The acute lymphocytic leukemia therapeutics market has growth potential as the incidence rate of the disease is increasing all over the globe. The incidence of acute lymphocytic leukemia is...

2013-12-10 16:25:09

-- Clinical Presentation in Waldenstrom's Macroglobulinemia Deemed "Best of ASH" -- NEW ORLEANS, Dec. 10, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA((TM))) at the 55(TH) Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013. There were seven presentations of clinical data, of which five were oral presentations, including...

2013-12-10 08:30:39

DALLAS, December 10, 2013 /PRNewswire/ -- The "Acute Lymphocytic Leukemia Therapeutics Market (Pipeline Forecast & Market Forecast in G8 Countries) (2010 - 2020)" analyzes and studies the major market drivers, restraints, and opportunities in the U.S., Canada, U.K., France, Germany, Italy, Spain, and Japan. Browse 50 Market Data Tables and 28 Figures spread through 157 Pages and in-depth TOC on "Acute Lymphocytic Leukemia Therapeutics Market"...

2013-12-09 20:22:53

-- Estimated progression-free survival at 24 months was 96.3 percent in this Phase 1b/2 trial-- SUNNYVALE, Calif., Dec. 9, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that The Lancet Oncology published results of a study evaluating ibrutinib in previously untreated elderly patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The Phase 1b/2 open-label, multicenter study evaluated 31 patients, 65 years of age and older with...

2013-12-09 20:22:46

Encouraging Data from a Phase 1b/2, Open-label, Multicenter Study RARITAN, N.J., Dec. 9, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced data from a study published in The Lancet Oncology, evaluating the safety and activity of ibrutinib as a single-agent therapy in patients over the age of 65 with previously untreated chronic lymphocytic leukemia (CLL, N=29) or small lymphocytic lymphoma (SLL, N=2). The study met its primary endpoint of safety, with data...

Engineered Immune Cells Fight Cancer
2013-12-09 14:30:13

Brett Smith for redOrbit.com - Your Universe Online Researchers from the University of Pennsylvania and the Children’s Hospital of Philadelphia have been able to reprogram the body’s immune system to fight leukemia, with 89 percent of children and adults in a series of clinical trials showing no evidence of cancer after receiving a personalized cell therapy. The findings from the first 59 patients to receive this cutting-edge therapy, known as CTL019, were presented during the...

2013-12-09 10:12:57

A series of advancements in genetically engineered cell therapies demonstrate early efficacy and safety in patients with blood disorders for whom standard treatments have been unsuccessful, according to data showcased today during the 55th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans. Today, many patients with newly diagnosed blood disorders – ranging from cancer to rare genetic conditions – respond well to modern treatment regimens. However, for...

Genetically Modified Cells Produce Long-term Remissions
2013-12-09 06:46:50

University of Pennsylvania School of Medicine Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children's Hospital of Philadelphia will today announce the latest results of studies involving both adults and children with advanced blood cancers that have failed to respond to...

2013-12-08 12:21:19

NEW ORLEANS, Dec. 8, 2013 /PRNewswire-USNewswire/ -- Several new, targeted therapies show promise to expand treatment options for chronic lymphocytic leukemia (CLL) and are more effective and better tolerated than standard chemotherapy, according to studies presented today during the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans. CLL is a blood cancer that occurs when abnormal white blood cells called lymphocytes accumulate in the blood, bone...